Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2018

Swami Umang, Ma Deqin, Zhang Jun

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Prognosis

Share to Sequence Deletion

Source

Identifiers

PMID: 29935854
DOI: 10.1016/j.jtho.2018.03.034

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion.PMID 29935854Read ↗

Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.Semantic proximity Read ↗

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.Semantic proximity Read ↗

Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.Semantic proximity Read ↗

A rare EGFR mutation L747P conferred therapeutic efficacy to both geﬁtinib and osimertinib: A case report.Semantic proximity Read ↗

Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report.Semantic proximity Read ↗

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.Semantic proximity Read ↗

Are 19del and L858R really different disease entities?Semantic proximity Read ↗

EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature reviewSemantic proximity Read ↗

Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation.Semantic proximity Read ↗

[Differences between EGFR Exon 19 Deletion and Exon 21 L858R Point Mutation, Frequently Detected EGFR Mutations in Patients with Non-Small Cell Lung Cancer, from a Molecular Biology Viewpoint].Semantic proximity Read ↗

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.Semantic proximity Read ↗

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.